Table 1.
Plasma pharmacokinetics of 125I-Aβ40 and 125I-Aβ42 in WT and APP/PS1 transgenic mice at 8, 24, and 52 weeks
| Wild-type | ||||||
|---|---|---|---|---|---|---|
| Age (weeks) |
125I-Aβ40 |
125I-Aβ42 |
||||
| Cmax (μCi/mL) | AUC (μCi.min/mL) | Clearance (mL/min) | Cmax (μCi/mL) | AUC (μCi.min/mL) | Clearance (mL/min) | |
|
| ||||||
| 8 | 23.2 ± 0.6 | 63.5 ± 6.5 | 1.6 ± 0.2 | 11.3 ± 0.5### | 78.9 ± 11.8 | 1.3 ± 0.2 |
| 24 | 16.4 ± 0.4 | 43.5 ± 3.1 | 2.3 ± 0.2 | 5.2 ± 0.3### | 40.1 ± 9.4 | 2.5 ± 0.3* |
| 52 | 12.8 ± 0.1 | 373 ± 63*** | 0.26 ± 0.04** | 6.0 ± 0.3### | 31.2 ± 3.5#### | 3.2 ± 0.3*** |
|
| ||||||
| APP/PS1 | ||||||
|
| ||||||
| 8 | 17.7 ± 1.8 | 49.7 ± 12.4 | 2.1 ± 0.5 | 3.4 ± 0.3### | 27.6 ± 9.4 | 3.6 ± 1.2 |
| 24 | 12.5 ± 0.2 | 103.0 ± 34.5 | 1.0 ± 0.3 | 7.1 ± 0.2## | 72.2 ± 19.7 | 1.4 ± 0.3 |
| 52 | 13.7 ± 0.2 | 86.8 ± 22.8 | 1.2 ± 0.3 | 5.1 ± 1.0### | 30.9 ± 7.8 | 3.2 ± 0.8 |
Data represent mean±SE, n = 3–5. Significance was assessed over age (*p<0.05, **p<0.01, and ***p<0.001) and 125I-Aβ40 versus 125I-Aβ42 (##p<0.01, ###p<0.001, and ###p<0.0001; two-way ANOVA with Bonferroni post-tests).